Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.

By W. Busse, S. Holgate, E. Kerwin, Y. Chon, J. Feng, Joseph H. Lin, Shao-Lee Lin. American Journal of Respiratory and Critical Care Medicine, 2013

594 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Physiology

View Paper: https://www.semanticscholar.org/paper/b77678e07a3aa4818f9ad3f81b187a7ff9905d46

Citations in the corpus

• Performance of a Natural Language Processing (NLP) Tool to Extract Pulmonary Function Test (PFT) Reports from Structured and Semistructured Veteran Affairs (VA) Data (2016, unknown): “A recent randomized, placebo-controlled study examining Brodalumab, a human anti-IL 17 receptor monoclonal antibody, reported a suggestive treatment effect only among study participants with asthma classified as having high bronchodilator reversibility.(6) High bronchodilator reversibility may serve”